Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time
- 18 October 2000
- journal article
- review article
- Published by Elsevier in Current Opinion in Microbiology
- Vol. 3 (5) , 515-521
- https://doi.org/10.1016/s1369-5274(00)00132-6
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- LIMITATIONS OF SINGLE POINT PHARMACODYNAMIC ANALYSISThe Pediatric Infectious Disease Journal, 2000
- Pharmacodynamics of LevofloxacinJAMA, 1998
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisAntimicrobial Agents and Chemotherapy, 1993
- ARTs versns ASTs: where are we going?Journal of Antimicrobial Chemotherapy, 1991
- Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection modelAntimicrobial Agents and Chemotherapy, 1991
- Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistanceAntimicrobial Agents and Chemotherapy, 1987
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987
- In Vitro Veritas? Antimicrobial Susceptibility Tests and Their Clinical RelevanceThe Journal of Infectious Diseases, 1981